Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9625482 | 0.87 | CHRM2 (0.63) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL26077666 | 0.87 | ALDH1A1 (0.47) | CHRM2ALDH1A1MEN1KMT2ACA12 | |
| SCHEMBL7286379 | 0.85 | CHRM2 (0.53) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL13484325 | 0.83 | ALDH1A1 (0.52) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL28964583 | 0.83 | CHRM2 (0.51) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL5681593 | 0.83 | CHRM2 (0.51) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL30214381 | 0.83 | CHRM2 (0.51) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL3170290 | 0.83 | ALDH1A1 (0.52) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL16715916 | 0.82 | CHRM2 (0.50) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL799700 | 0.82 | CHRM2 (0.58) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | SAINT JOSEPH'S UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | SAINT JOSEPH'S UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2022167637-A1 | PROCESS FOR MODIFYING AN AROMATIC POLYETHER BACKBONE AND A MODIFIED POLYETHER OBTAINED BY THIS PROCESS | Technische Universität Berlin (DE) | 2022-08-11 | — | — | WO | disclosed |
| US-20220162235-A1 | LUMINESCENT SILAFLUORENE AND GERMAFLUORENE COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2022-05-26 | — | — | US | disclosed |
| US-20200407375-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | UNIVERSITY OF THE SCIENCES (US) | 2020-12-31 | — | — | US | disclosed |
| WO-2020147739-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9199923-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100010250-A1 | METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE | Draximage Limited (IE) | 2010-01-14 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-20 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | CHRM2 55/4885ALDH1A1 2674/4885MEN1 761/4885 |
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | TXN2, ABCB7, TXN | CHRM2 4366/4885ALDH1A1 967/4885MEN1 1702/4885 |
| US-20200407375-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | ABCB7, TXN2, PRDX3 | CHRM2 4054/4885ALDH1A1 792/4885MEN1 2040/4885 |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CHRM2 4368/4885ALDH1A1 955/4885MEN1 619/4885 |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | CHRM2 4856/4885ALDH1A1 786/4885MEN1 2788/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | CHRM2 4722/4885ALDH1A1 320/4885MEN1 4444/4885 |
| US-20090209615-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES TO TREAT NEUROLOGICAL DISORDERS | MMP9, MMP10, MMP17 | CHRM2 3245/4885ALDH1A1 288/4885MEN1 1748/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CHRM2 4712/4885ALDH1A1 764/4885MEN1 888/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | CHRM2 4077/4885ALDH1A1 682/4885MEN1 2729/4885 |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | CHRM2 2060/4885ALDH1A1 2251/4885MEN1 210/4885 |
| US-20220162235-A1 | LUMINESCENT SILAFLUORENE AND GERMAFLUORENE COMPOUNDS | SLCO2A1, GLO1, GLMN | CHRM2 4459/4885ALDH1A1 1331/4885MEN1 2475/4885 |
| US-20100010250-A1 | METHODS FOR PREPARING 2-METHOXYISOBUTYLISONITRILE AND TETRAKIS(2-METHOXYISOBUTYLISONITRILE)COPPER(I) TETRAFLUOROBORATE | MEN1, CYP2F1, CYP4F11 | CHRM2 3470/4885ALDH1A1 2915/4885MEN1 1/4885 |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CHRM2 4712/4885ALDH1A1 764/4885MEN1 888/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | CHRM2 3176/4885ALDH1A1 750/4885MEN1 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.